Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary fibrosis (IPF). In this blog,

In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely and efficient provision of fit

Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh from Pharmidex organised a meeting

As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting on the return of in-person

What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our website, here’s how a typical

In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets disease, target a mechanism, and

In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D,